Associations between lean mass and leptin in men with chronic spinal cord injury: Results from the FRASCI-muscle study

Andrew J. Park¹, Ricardo A. Battaglino¹, Nguyen M. H. Nguyen², Leslie R. Morse¹,2*

¹ Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Aurora, Colorado, United States of America, ² Rocky Mountain Regional Spinal Injury System, Craig Rehabilitation Hospital, Englewood, Colorado, United States of America

* lmorse@craighospital.org

Abstract

Leptin is an adipokine that regulates appetite and energy expenditure by a neuroendocrine feedback loop. Leptin levels are positively correlated with BMI in the spinal cord injury population and leptin levels are greater in individuals with spinal cord injury compared to uninjured controls. Leptin is produced in multiple tissues, including fat, bone, and skeletal muscle and is a putative biomarker of sedentary behavior in older adults. We assessed body composition leptin, adiponectin, and IL-6 levels in 205 men with chronic spinal cord injury. We found no association between age, injury duration, injury level, injury completeness, or walking status and leptin. There was a significant positive association between lean mass and leptin in men with SCI that was independent of fat. Adjusting for body composition, leptin levels were positively associated with IL-6 and negatively associated with adiponectin levels. When considering men with SCI and sarcopenic obesity, only fat mass remained positively associated with leptin. We found no association between IL-6, adiponectin, or lean mass and leptin in the sarcopenic obesity group. Our findings suggest that lean mass is an under recognized, but substantial, source of circulating leptin. Furthermore, SCI-related sarcopenic obesity may result in dysregulated adipo-myokine metabolism with local and systemic physiologic effects.

Introduction

Leptin has classically been identified as an adipokine produced by adipocytes that regulates weight balance and energy expenditure by a neuroendocrine feedback loop between adipose tissue and the hypothalamus [1]. Transgenic mice lacking leptin receptor isoforms consistently demonstrate an obese phenotype with significantly more adipose tissue and less lean mass compared to wild type mice [2]. In human studies, leptin levels are positively correlated with obesity in the general population [3] and positively associated with sedentary behavior, even after adjusting for various possible confounding factors including demographics, medications, and body mass index (BMI) [4–6]. However, the frail elderly with high prevalence of low lean mass defined as sarcopenia have low leptin levels and higher leptin levels are associated with
increased longevity in centenarians, suggesting a role for leptin in skeletal muscle metabolism [7].

Leptin receptors are abundant in human skeletal muscle [8]. Leptin is produced by and regulates skeletal muscle directly through myoblast leptin receptors in an autocrine fashion [2, 9–14] and through a central neuroendocrine pathway that is mediated by insulin-like growth factor 1 (IGF-1) [15–16]. An elegant in vivo study demonstrated that skeletal muscle produces leptin and that the per unit mass of leptin release from adipose tissue is only slightly greater than skeletal muscle in humans[9]. The endocrine function of muscle has been studied extensively and has led some to use the term “adipo-myokine” for cytokines that are produced in both muscle and fat and signal in an autocrine or paracrine manner, such as leptin and interleukin-6 (IL-6). As skeletal muscle represents a greater total body composition percentage than adipose tissue, skeletal muscle may play a greater role in leptin production and regulation than previously appreciated. These findings suggest that muscle may be an important source of circulating leptin and that muscle disorders, including atrophy and sarcopenia, may impact the autocrine functions of muscle-derived leptin.

Obesity, sedentary behavior, and sarcopenia are all prevalent after spinal cord injury (SCI). Several studies have reported that people with SCI have higher leptin levels than non-injured controls [10, 17–22]. These results are consistent with known body composition changes that occur after SCI, including increased total fat mass and lower lean mass [23]. Obesity increases the production and release of pro-inflammatory adipokines, including leptin and IL-6. This occurs with a simultaneous reduction of anti-inflammatory adipokines, including adiponectin. The impact of this shift in balance between pro- and anti-inflammatory cytokines on muscle-fat interactions is poorly understood and there is limited information on these interactions following SCI. Therefore, in this study we sought to assess the association between circulating adipo-myokines and lean mass in men with chronic SCI.

Materials and methods

Subjects

For this muscle sub study, we assessed participants with chronic SCI who were enrolled in the longitudinal Fracture Risk after SCI (FRASCI) Study. Study inclusion criteria and recruitment methods for the parent cohort study have previously been described [24–25]. Briefly, participants with SCI were eligible if they were 22 years of age or older, one or more years after injury, were not ventilator dependent, did not have a tracheostomy, and had no other neuromuscular disease. 348 participants with SCI were enrolled in this cohort between August 2009 and December 2014 and completed testing. We excluded 51 subjects because body composition (n = 21) or biomarker results (n = 30) were not available. We excluded women with SCI (n = 35), as there were too few to make meaningful comparisons based on gender. We also excluded 54 participants actively taking medications known to influence bone metabolism [bisphosphonates (n = 23), warfarin (n = 16), hormones (n = 10), bisphosphonate + warfarin (n = 3), bisphosphonate + hormone (n = 2)]. 3 participants (72,175.3–122,358.5 pg/mL) excluded based on leptin levels that were considered to be outliers. The final cohort for this muscle sub study (FRASCI-muscle) consisted of 205 men with SCI (Fig 1). The Institutional Review Boards approved all protocols prior to initiation of the study, and all participants gave their written informed consent to participate.

Motor score

Motor level and completeness of injury were confirmed by physical exam at study entry by a trained rater according to the American Spinal Injury Association Impairment Scale (AIS).
Participants were classified as AIS A or B (motor complete, no motor function below the neurological level of injury); AIS C (motor incomplete, motor function preserved below the neurological level, and more than half the key muscles below the neurological level are not strong enough to overcome gravity); or AIS D (motor incomplete, motor function preserved below the neurological level, and more than half the key muscles below the neurological level strong enough to overcome gravity). Injury severity was then classified in 2 categories: motor complete SCI (AIS A/B) or motor incomplete SCI (AIS C or D).

**Dual X-ray absorptiometry (DXA) for body composition**

We used a 5th generation GE Healthcare iDXA dual x-ray absorptiometry (DXA) scanner with enCore configuration version 12.3 to assess body composition. Total fat mass (kg) and total lean mass (kg) were calculated by the system software from whole body scans based on body weight measured at the time of scanning. As a standard procedure, a quality assurance phantom supplied by the manufacturer was measured at least every 2 days to confirm accuracy of the densitometer.

**Biochemical analyses**

Subjects were asked to undergo testing in a fasting state and efforts were made to collect samples in the morning before a meal. For subject safety, individuals were advised to have a light
meal or snack if fasting could worsen a medical condition (orthostatic hypotension). In all cases information was collected on time since last meal or snack. Plasma samples were drawn into an EDTA tube and immediately delivered to the core blood research laboratory at our facility. The samples were centrifuged for 15 min at 2600 rpm (1459 x g) at 4˚C and stored at -80˚C until batch analysis. All biochemical analyses were performed at the Clinical & Epidemiologic Research Laboratory, Department of Laboratory Medicine at Children’s Hospital in Boston, a state-of-the-art reference laboratory that specializes in micro-analysis. Leptin was measured by ultra-sensitive enzyme linked immunosorbent assay (ELISA) (R & D Systems, Minneapolis, MN) with a sensitivity of 7.8 pg/mL and day-to-day variability of 5.4, 4.2 and 3.5% at concentrations of 65.7, 146 and 581 pg/mL, respectively. Total adiponectin was measured by ELISA (ALPCO Diagnostics Inc., Salem, NH) with a detection limit of 0.075 ng/ml and day-to-day variability less than 15% at various concentrations for all forms of adiponectin. Interleukin-6 (IL-6) was determined by ultra-sensitive ELISA (R & D Systems, Minneapolis, MN) with a sensitivity of 0.094 pg/ml and day-to-day variability of 9.6, 7.2 and 6.5% at concentrations of 0.49, 2.78 and 5.65 pg/mL, respectively. Assays were performed in duplicate and any duplicate with >10% CV was repeated.

**Variable definition**

Information regarding SCI, medical history, and medication use was obtained by questionnaire at the time of DXA scan. Participants were weighed and supine length measured for the calculation of body mass index (BMI). In subjects with severe joint contractures, length was self-reported (n = 14). Usual mobility mode (more than 50% of the time) was considered in the following 2 categories: wheelchair use (motorized wheelchair or hand-propelled wheelchair) or walking (with aid such as crutch, cane or walk without assistance). Obesity was defined as having a BMI ≥ 25 for SCI [26,27]. Sarcopenia was defined as having an appendicular lean mass index ≤ 7.26 [27]. Sarcopenic-obesity was defined as being sarcopenic (ALMI ≤ 7.26) and having total body % fat ≥ 25 [26,27]. For body composition total lean mass (kg) was included in the analyses.

**Statistical analysis**

All analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC). T-tests or χ² tests were used to compare subject characteristics as appropriate. General linear models (PROC GLM) were applied to assess associations between leptin and lean mass. Factors with a p value of <0.10 in the univariate models, as well as factors that were deemed clinically significant (age), were included in the multivariable models assessing the association of lean mass and leptin (PROC GLM). Factors with a p value of <0.05 were considered statistically significant and any factor with a p value of >0.05 was removed from the models.

**Results**

**Subject characteristics**

Subject characteristics are presented in Table 1. All participants were male and the majority white. Ages ranged from 22.7 to 85.7 years with a mean of 54.3 ± 13.7. Injury duration ranged from 4.7 to 30.7 years with a mean of 17.7 ± 13.0 years. Nearly 60% of participants used a wheelchair as their primary mobility mode with the majority (72%) using manual wheelchairs. A majority of the subjects were obese (68%), had sarcopenia (31%), and/or had sarcopenic-obesity (27%). A majority of subjects (79%) had not consumed anything for at least 8 hours
prior to testing. Leptin, adiponectin, and IL-6 levels did not vary significantly based on time since last meal or snack (p = 0.41 for leptin, p = 0.14 for adiponectin, and p = 0.45 for IL-6).

Clinical factors associated with ln leptin levels

In univariate analyses leptin levels were positively associated with injury duration, BMI, fat mass, total lean mass, IL-6, and obesity status and were negatively associated with adiponectin and sarcopenia status (Table 2). Age, walking status, tetraplegia vs paraplegia did not reach significance. In multivariate models that included all men with SCI (Table 3), ln leptin was negatively associated with ln adiponectin (p = 0.001) and positively associated with total lean mass, total fat mass, and ln IL-6 (p = 0.001-<0.0001). Leptin levels increased by 1.09 pg/mL for every 1% increase in fat mass and by 1.02 pg/mL for every kilogram increase in lean mass. This model explained 73% of the variation in ln leptin. These relationships remained unchanged in multivariable models restricted to men with SCI and no sarcopenic-obesity (p = 0.001-<0.0001). However, when limiting the analysis to men with SCI and sarcopenic obesity, only total fat mass remained positively associated with ln leptin (p = <0.0001). Leptin levels also increased by 1.08 pg/mL for every 1% increase in fat mass in this group. We found no significant association between ln leptin and lean mass or ln adiponectin (p = 0.27–0.30). There was a positive association between ln IL-6 and ln leptin that trended toward significance (p = 0.06). This model explained 73% of the variation in ln leptin.

Discussion

We examined body composition and circulating levels of leptin in 205 men with chronic SCI. We found no association between age, injury duration, injury level, injury completeness, or
walking status and leptin. There was a significant positive association between lean mass and leptin in men with SCI that was independent of fat. Adjusting for body composition, leptin levels were positively associated with IL-6 and negatively associated with adiponectin levels. When considering men with SCI and sarcopenic obesity, only fat mass remained positively associated with leptin. We found no association between IL-6, adiponectin, or lean mass and leptin in the sarcopenic obesity group.

Our findings suggest that lean mass contributes independently to circulating leptin levels in men with SCI with normal body composition. These results suggest sarcopenia leads to impaired leptin production and/or release from skeletal muscle following SCI. In the current study nearly one third of the men with SCI were sarcopenic and 27% had sarcopenic-obesity.

Table 2. Univariate factors associated with ln leptin in men with chronic SCI.

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Age (years)               | 0.009 ± 0.005 | 0.07 |
| Injury duration (years)   | 0.01 ± 0.005 | 0.03 |
| BMI (kg/m²)               | 0.12 ± 0.008 | <0.0001 |
| Total fat mass (%)        | 0.095 ± 0.004 | <0.0001 |
| Total lean mass (kg)      | 0.03 ± 0.007 | <0.0001 |
| ln adiponectin (ng/ml)    | -0.63 ± 0.11 | <0.0001 |
| ln IL-6 (ng/ml)           | 0.51 ± 0.06 | <0.0001 |

Walking status

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Wheelchair user           | 0.08 ± 0.13 | 0.57 |
| Walk with or without aid  | reference |       |

Injury completeness

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Motor complete            | 0.06 ± 0.13 | 0.65 |
| Motor incomplete          | reference |       |

Injury level

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Tetraplegia               | -0.13 ± 0.13 | 0.31 |
| Paraplegia                | reference |       |

Obesity status

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Obese                     | 1.25 ± 0.11 | <0.0001 |
| Not obese                 | reference |       |

Sarcopenia status

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Sarcopenia                | -0.37 ± 0.14 | 0.008 |
| No sarcopenia             | reference |       |

Sarcopenic-obesity status

| Variable                  | β ± SE   | p     |
|---------------------------|----------|-------|
| Sarcopenic-obesity        | -0.12 ± 0.15 | 0.41 |
| No sarcopenic-obesity     | reference |       |

Table 3. Multivariable model of factors associated with ln leptin in men with SCI and based on sarcopenic-obesity status.

| Variable                  | β ± SE   | eβ   | p     | β ± SE   | eβ   | p     | β ± SE   | eβ   | p     |
|---------------------------|----------|------|-------|----------|------|-------|----------|------|-------|
| Total fat mass (%)        | 0.08 ± 0.004 | 1.08 | <0.0001 | 0.09 ± 0.006 | 1.09 | <0.0001 | 0.09 ± 0.009 | 1.09 | <0.0001 |
| Total lean mass (kg)      | 0.02 ± 0.003 | 1.02 | <0.0001 | 0.02 ± 0.005 | 1.02 | 0.001 | 0.01 ± 0.01 | 1.01 | 0.30 |
| ln adiponectin            | -0.21 ± 0.06 | 0.81 | 0.001 | -0.23 ± 0.08 | 0.79 | 0.005 | -0.15 ± 0.13 | 0.86 | 0.27 |
| ln IL-6                   | 0.14 ± 0.04 | 1.15 | 0.001 | 0.16 ± 0.05 | 1.17 | 0.003 | 0.15 ± 0.08 | 1.16 | 0.06 |

https://doi.org/10.1371/journal.pone.0198969.t002

https://doi.org/10.1371/journal.pone.0198969.t003
These results are consistent with a previous study demonstrating high prevalence of sarcopenic obesity in adults with SCI [26]. Extreme muscle wasting begins immediately with a 33% reduction in thigh cross-sectional area within 3 months after SCI, and occurs with both increased intramuscular fat accumulation and increased central adiposity [28]. It is possible that intramuscular fat is a significant source of muscle-derived leptin. Our findings of lower leptin levels in those with sarcopenia versus those with normal muscle mass suggests that intramuscular fat is not the primary source of muscle-derived leptin. However, our study design did not include assessments of intramuscular fat. Future studies focused on associations between intramuscular fat and circulating leptin are needed to test this hypothesis.

Crosstalk between muscle and adipose tissue is poorly understood, but it is well documented in both mouse and human studies that leptin receptors are abundant in high concentrations in skeletal muscle and that skeletal muscle produces leptin [8,9,11,29]. Leptin, recently identified as an adipo-myokine, may link the metabolic rate of skeletal muscle to fat mass and therefore nutrient availability. Indeed, coordinated muscle-adipose metabolism has been reported in several studies [30–33]. Moreover, a high-fat diet increases leptin expression in both skeletal muscle and adipose tissue [29,34]. Leptin, therefore, likely plays a critical role in maintaining balance between adipose tissue and skeletal muscle mass.

Previous literature commonly credits increased central adiposity as the cause of elevated leptin levels after SCI without considering the contributions of skeletal muscle [35]. Nonetheless, perpetual elevation of circulating leptin levels may have multiple consequences on the central neuroendocrine pathway. Leptin is well known to participate in energy homeostasis by interaction with the long form leptin receptor LepRb which activates Jak2/Stat3 pathway in the arcuate nucleus of the hypothalamus. This ultimately triggers various signaling cascades in metabolism including suppression of feeding behavior [36–39]. After prolonged activation of the LepRb receptor, the downstream activation of the SOCS3 pathway appears to attenuate LepRb receptors leading to leptin resistance [36]. Chronic SCI leads to reduction in LepRb and Jak2/Stat3 signaling and additionally increases expression of SOCS3, consistent with a central leptin resistance after SCI [37]. Additionally, persistent down stream signaling results in attenuation of anorexigenic neuroendocrine pathways and disinhibition leading to pro-orexigenic effects. Persistent activation of these pathways likely contribute to metabolic dysfunction [38]. Paradoxically, elevated leptin levels appear to have the opposite effect on peripheral leptin receptor expression following SCI. Leptin receptors and downstream pro-inflammatory pathways are significantly increased in several visceral organs, including pancreatic and cardiac tissue [38]. This is particularly relevant given the high prevalence of cardiovascular disease after SCI [35]. This divergent leptin expression and regulation from central and peripheral tissues has previously been described as selective leptin resistance, although a mechanism for these differences has not yet been identified [39].

The impact of SCI-induced sarcopenia on leptin signaling within skeletal muscle and systemically is unknown. It is also unclear if muscle-derived leptin and fat-derived leptin have unique targets in their local environments, in the periphery, or centrally. We do know that obesity and exercise both influence the balance of pro-inflammatory and anti-inflammatory cytokines including leptin [40–42], and that distinct leptin receptor isoforms have been described in human skeletal muscle and adipose tissue [8]. Additionally, differences in co-expression of cytokines in skeletal muscle versus adipose tissue may result in distinct local signaling milieus. The ratio of leptin to adiponectin is positively associated with muscle strength in older adults [22] and is a biomarker of atherosclerotic disease, insulin resistance, and metabolic syndrome in the general population [43]. Similarly, IL-6 is produced by both contracting skeletal muscle and adipose tissue and regulates adipogenesis and production of adiponectin [44]. It has been suggested that obesity-related inflammatory cytokines, including tumor
necrosis factor α (TNFα), interleukin-1β (IL-1β) and IL-6, may accelerate muscle catabolism [45–47]. Muscle loss does not appear to plateau in chronic SCI [48], suggesting that fat-mediated mechanisms compound the effects of mechanical unloading on muscle atrophy. In the current study, leptin levels were negatively associated with adiponectin levels and positively associated with IL-6, and this is consistent with prior reports [10]. Interestingly, there was no longer a significant association between leptin and IL-6 or adiponectin in men with SCI and sarcopenic obesity. These findings support the concept of dysregulated adipo-myokine activity in men with SCI with sarcopenic obesity.

**Conclusion**

Skeletal muscle mass is positively associated with leptin in men with chronic SCI and normal body composition. The development of SCI-induced sarcopenic obesity disrupts muscle/leptin associations suggesting dysregulated adipo-myokine activity. The systemic consequences of abnormal skeletal muscle-derived leptin production and/or release are unclear and warrant further investigation.

**Author Contributions**

**Conceptualization:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen, Leslie R. Morse.

**Data curation:** Nguyen M. H. Nguyen, Leslie R. Morse.

**Formal analysis:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen, Leslie R. Morse.

**Funding acquisition:** Leslie R. Morse.

**Investigation:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen, Leslie R. Morse.

**Methodology:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen, Leslie R. Morse.

**Project administration:** Leslie R. Morse.

**Software:** Nguyen M. H. Nguyen.

**Supervision:** Leslie R. Morse.

**Validation:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen, Leslie R. Morse.

**Writing – original draft:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen.

**Writing – review & editing:** Andrew J. Park, Ricardo A. Battaglino, Nguyen M. H. Nguyen, Leslie R. Morse.

**References**

1. Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci. 2002 Jun; 967:379–88. PMID: 12079865

2. Arounleut P, Bowser M, Upadhyay S, Shi X-M, Fulzele S, Johnson MH, et al. Absence of functional leptin receptor isoforms in the POUND (Lepr(db/lb)) mouse is associated with muscle atrophy and altered myoblast proliferation and differentiation. PloS One. 2013; 8(8):e72330. https://doi.org/10.1371/journal.pone.0072330 PMID: 23967295

3. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996 Feb 1; 334(5):292–5. https://doi.org/10.1056/NEJM199602013340503 PMID: 8532024

4. Allison MA, Jensky NE, Marshall SJ, Bertoni AG, Cushman M. Sedentary behavior and adiposity-associated inflammation: the Multi-Ethnic Study of Atherosclerosis. Am J Prev Med. 2012 Jan; 42(1):8–13. https://doi.org/10.1016/j.amepre.2011.09.023 PMID: 22176840
Lean mass and leptin in spinal cord injury

5. Larsen BA, Allison MA, Kang E, Saad S, Laughlin GA, Araneta MRG, et al. Associations of physical activity and sedentary behavior with regional fat deposition. Med Sci Sports Exerc. 2014 Mar;46(3):520–8. https://doi.org/10.1249/MSS.0b013e3182a77220 PMID: 23924920

6. Henson J, Yates T, Edwardson CL, Khunti K, Talbot D, Gray LJ, et al. Sedentary time and markers of chronic low-grade inflammation in a high risk population. PloS One. 2013;8(10):e78350. https://doi.org/10.1371/journal.pone.0078350 PMID: 24205208

7. Pareja-Galeano H, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Garatachea N, Gálvez BG, et al. Circulating leptin and adiponectin concentrations in healthy exceptional longevity. Mech Ageing Dev. 2017 Mar;162:129–32. https://doi.org/10.1016/j.mad.2016.02.014 PMID: 26944227

8. Guerra B, Santana A, Fuentes T, Delgado-Guerra S, Cabrera-Socorro A, Dorado C, et al. Leptin receptors in human skeletal muscle. J Appl Physiol Bethesda Md 1985. 2007 May;102(5):1786–92.

9. Wolsk E, Mygind H, Grendahl TS, Pedersen BK, van Hall G. Human skeletal muscle releases leptin in vivo. Cytokine. 2012 Dec;60(3):667–73. https://doi.org/10.1016/j.cyto.2012.08.021 PMID: 23010500

10. Wang Y-H, Huang T-S, Liang H-W, Su T-C, Chen S-Y, Wang T-D. Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury. Arch Phys Med Rehabil. 2005 Oct;86(10):1964–8. https://doi.org/10.1016/j.apmr.2005.04.017 PMID: 16213329

11. Solberg R, Aas V, Thoresen GH, Kase ET, Drevon CA, Rustan AC, et al. Leptin expression in human primary skeletal muscle cells is reduced during differentiation. J Cell Biochem. 2005 Sep 1;96(1):89–96. https://doi.org/10.1002/jcb.20521 PMID: 16052473

12. Fernández-Real JM, Vayreda M, Casamitjana R, González-Huix F, Ricart W. The fat-free mass compartment influences serum leptin in men. Eur J Endocrinol. 2000 Jan;142(1):25–9. PMID: 10633217

13. Sáinz N, Rodríguez A, Catalián V, Becerril S, Ramírez B, Gómez-Ambrosi J, et al. Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice. PloS One. 2009 Sep 4;4(9):e6808. https://doi.org/10.1371/journal.pone.0006808 PMID: 19730740

14. Hamrick MW. Role of the Cytokine-like Hormone Leptin in Muscle-bone Crosstalk with Aging. J Bone Metab. 2017 Feb;24(1):1–8. https://doi.org/10.11055/jbm.2017.24.1.1 PMID: 28326295

15. Bartell SM, Rayalam S, Ambati S, Gaddam DR, Hartzell DL, Hamrick MW, et al. Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011 Aug;26(8):1710–20.

16. Hamrick MW, Dukes A, Arounleut P, Davis C, Periyasamy-Thanavaran S, Mork S, et al. The adipokine leptin mediates muscle- and liver-derived IGF-1 in aged mice. Exp Gerontol. 2015 Oct;70:92–6. https://doi.org/10.1016/j.exger.2015.07.014 PMID: 26220769

17. Lattifi S, Koushki D, Norouzi Javidan A, Matin M, Sabour H. Changes of leptin concentration in plasma in patients with spinal cord injury: a meta-analysis. Spinal Cord. 2013 Oct;51(10):728–31. https://doi.org/10.1038/sc.2013.82 PMID: 23999108

18. Huang TS, Wang YH, Chen SY. The relation of serum leptin to body mass index and to serum cortisol in men with spinal cord injury. Arch Phys Med Rehabil. 2000 Dec;81(12):1582–6. https://doi.org/10.1053/apmr.2000.9173 PMID: 11128893

19. Jeon JY, Steadward RD, Wheeler GD, Bell G, McCargar L, Harber V. Intact sympathetic nervous system is required for leptin effects on resting metabolic rate in people with spinal cord injury. J Clin Endocrinol Metab. 2003 Jan;88(1):402–7. https://doi.org/10.1210/jc.2002-020939 PMID: 12519883

20. Maimoun L, Puech A-M, Manetta J, Badiou S, Paris F, Ohanna F, et al. Circulating leptin concentrations can be used as a surrogate marker of fat mass in acute spinal cord injury patients. Metabolism. 2004 Aug;53(8):989–94. PMID: 15281006

21. Maruyama Y, Mizuguchi M, Yaginuma T, Kusaka M, Yoshida H, Yokoyama K, et al. Serum leptin, abdominal obesity and the metabolic syndrome in individuals with chronic spinal cord injury. Spinal Cord. 2008 Jul;46(7):494–9. https://doi.org/10.1038/sj.sc.3102171 PMID: 18209743

22. Bucci L, Yani SL, Fabbri C, Bjilasma AY, Maier AB, Meskers CG, et al. Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength of young and old healthy subjects. Biogerontology. 2013 Jun;14(3):261–72. https://doi.org/10.1007/s10521-013-9428-5 PMID: 23666343

23. Spungen AM, Adkins RH, Stewart CA, Wang J, Pierson RN, Waters RL, et al. Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. J Appl Physiol Bethesda Md 1985. 2003 Dec;95(6):2398–407.

24. Doherty AL, Battaglino RA, Donovan J, Gagnon D, Lazzari AA, Garshick E, et al. Adiponectin is a candidate biomarker of lower extremity bone density in men with chronic spinal cord injury. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014 Jan;29(1):251–8.

25. Morse LR, Sudhakar S, Lazzari AA, Tun C, Garshick E, Zafonte R, et al. Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2013 Mar;24(3):961–8.
26. Pelletier CA, Miyatani M, Giangregorio L, Craven BC. Sarcopenic Obesity in Adults With Spinal Cord Injury: A Cross-Sectional Study. Arch Phys Med Rehabil. 2016 Nov; 97(11):1931–7. https://doi.org/10.1016/j.apmr.2016.04.026 PMID: 27282328

27. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. J. Am. Geriatr. Soc. 2010 Jul; 58(7):1678–84. https://doi.org/10.1111/j.1532-5415.2010.03136.x PMID: 20634373

28. Gorgey AS, Dudley GA. Skeletal muscle atrophy and increased intramuscular fat after incomplete spinal cord injury. Spinal Cord. 2007 Apr; 45(4):304–9. https://doi.org/10.1080/02648130601198968 PMID: 16940987

29. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature. 1998 Jun 18; 393(6686):684–8. https://doi.org/10.1038/31474 PMID: 9641678

30. Li Y, Li F, Lin B, Kong X, Tang Y, Yin Y. Myokine IL-15 regulates the crosstalk of co-cultured porcine skeletal muscle satellite cells and preadipocytes. Mol Biol Rep. 2014 Nov; 41(11):7543–53. https://doi.org/10.1007/s12053-014-9646-z PMID: 25098601

31. Ojima K, Oe M, Nakajima I, Shibata M, Chikuni K, Muroya S, et al. Proteomic analysis of secreted proteins from skeletal muscle cells during differentiation. EuPA Open Proteomics. 2014 Dec 1; 5:1–9.

32. Krzysik-Walker SM, Ocón-Grove OM, Maddineni SR, Hendricks GL, Ramachandran R. Is Visfatin an Adipokine or Myokine? Evidence for Greater Visfatin Expression in Skeletal Muscle than Visceral Fat in Chickens. Endocrinology. 2008 Apr 1; 149(4):1543–50. https://doi.org/10.1210/en.2007-1301 PMID: 18096661

33. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012 Jan 11; 481(7382):463. https://doi.org/10.1038/nature10777 PMID: 22237023

34. Wang J, Liu R, Liu L, Chowdhury R, Barzilai N, Tan J, et al. The effect of leptin on Lep expression is tissue-specific and nutritionally regulated. Nat Med. 1999 Aug; 5(8):895–9. https://doi.org/10.1038/11335 PMID: 10426312

35. Groah SL, Nash MS, Ward EA, Libin A, Mendez AJ, Burns P, et al. Cardiometabolic risk in community-dwelling persons with chronic spinal cord injury. J Cardiopulm Rehabil Prev. 2011 Apr; 31(2):73–80. https://doi.org/10.1097/HCR.0b013e3181f68aba PMID: 21045711

36. Villanueva EC, Myers MG. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes. 2005. 2008 Dec; 32(Suppl 7):S8–12.

37. Bigford GE, Bracchi-Ricard VC, Nash MS, Bethea JR. Alterations in mouse hypothalamic adipokine gene expression and leptin signaling following chronic spinal cord injury and with advanced age. PloS One. 2012; 7(7):e41073. https://doi.org/10.1371/journal.pone.0041073 PMID: 22913920

38. Bigford GE, Bracchi-Ricard VC, Keane RW, Nash MS, Bethea JR. Neuroendocrine and cardiac metabolic dysfunctions and NLRP3 inflammasome activation in adipose tissue and pancreas following chronic spinal cord injury in the mouse. ASBNEURO [Internet]. 2013 Sep 4 [cited 2017 Nov 22]; 5(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789215/

39. Mark AL, Correia MLG, Rahmouini K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002 Jul; 20(7):1245–50. PMID: 12131511

40. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014 Apr; 63(4):250–9. https://doi.org/10.1016/j.jcc.2013.11.006 PMID: 24355497

41. Rosey-Rodriguez M, Carnacho A, Rooste I, Fornieles G, Rosety MA, Diaz AJ, et al. Low-grade systemic inflammation and leptin levels were improved by arm cranking exercise in adults with chronic spinal cord injury. Arch Phys Med Rehabil. 2014 Feb; 95(2):297–302. https://doi.org/10.1016/j.apmr.2013.08.246 PMID: 24060491

42. Jeon JY, Hett ingen D, Steadward RD, Wheeler GD, Bell G, Harber V. Reduced plasma glucose and leptin after 12 weeks of functional electrical stimulation-rowing exercise training in spinal cord injury patients. Arch Phys Med Rehabil. 2010 Dec; 91(12):1957–9. https://doi.org/10.1016/j.apmr.2010.08.024 PMID: 21112441

43. López-Jaramillo P, Gómez-Arbélez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014 Apr; 18(1):37–45. https://doi.org/10.1515/hmcbi-2013-0053 PMID: 25389999

44. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012 Apr 3; 8(8):457–65. https://doi.org/10.1038/nrendo.2012.49 PMID: 22473333

45. Hoppeler H. Molecular networks in skeletal muscle plasticity. J Exp Biol. 2016 Jan; 219( Pt 2):205–13. https://doi.org/10.1242/jeb.128207 PMID: 26792332
46. Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, Albert V, Edom-Vovard F, Vidal-Puig A, et al. Human Adipocytes Induce Inflammation and Atrophy in Muscle Cells During Obesity. Diabetes. 2015 Sep; 64(9):3121–34. https://doi.org/10.2337/db14-0796 PMID: 25695947

47. Kelley DE, Goodpaster BH. Stewing in Not-So-Good Juices: Interactions of Skeletal Muscle With Adipose Secretions. Diabetes. 2015 Sep; 64(9):3055–7. https://doi.org/10.2337/db15-0403 PMID: 26294424

48. Moore CD, Craven BC, Thabane L, Laing AC, Frank-Wilson AW, Kontulainen SA, et al. Lower-extremity muscle atrophy and fat infiltration after chronic spinal cord injury. J Musculoskeletal Neuronal Interact. 2015 Mar; 15(1):32–41. PMID: 25730650